Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$3.17 USD
+0.01 (0.32%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $3.18 +0.01 (0.32%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.17 USD
+0.01 (0.32%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $3.18 +0.01 (0.32%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Zacks News
Mersana Stock Spikes on Interim Data on Cancer Candidate
by Zacks Equity Research
Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.
Why Mersana Therapeutics (MRSN) Stock Might be a Great Pick?
by Zacks Equity Research
Mersana Therapeutics (MRSN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why Mersana Therapeutics (MRSN) Spiked 69% Today
by Madeleine Johnson
Shares of biotech firm Mersana Therapeutics (MRSN) soared on Wednesday, closing up 69% to $18.19 per share. What was the cause
Top Ranked Momentum Stocks to Buy for May 20th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 20th.
Top Ranked Momentum Stocks to Buy for May 13th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 13th.
Top Ranked Momentum Stocks to Buy for April 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 20th
Top Ranked Momentum Stocks to Buy for April 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 14th
Will Mersana Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Mersana Therapeutics.
Mersana Therapeutics (MRSN) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Mersana Therapeutics (MRSN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Analysts Estimate Mersana Therapeutics, Inc. (MRSN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?
by Zacks Equity Research
Mersana Therapeutics (MRSN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.